JW (Cayman) Therapeutics Co Ltd

Common Name
JW (Cayman) Therapeutics
Country
China (Mainland)
Sector
Healthcare
Industry
Biotechnology
Employees
281
Ticker
2126
Exchange
HONG KONG EXCHANGES AND CLEARING LTD
Description
JW (Cayman) Therapeutics Co. Ltd. is a biopharmaceutical company focused on developing, manufacturing, and commercializing cell-based immunotherapies. The company primarily engages in the field of onc...

JW (Cayman) Therapeutics's Climate Target Data Preview

As of 2023, JW (Cayman) Therapeutics has disclosed 1 climate targets aimed at reducing its greenhouse gas (GHG) emissions. These include 1 intensity-based target, signaling the company’s commitment to managing and lowering its carbon footprint over time. The targets span various emissions scopes and time horizons, offering insight into JW (Cayman) Therapeutics ’s climate strategy, ambition level, and alignment with global decarbonization goals.

Target TypeScope of TargetUnitTargetTarget Year
Intensity-based Target
Scope 1 - Total, Scope 2 - Total
Metric Tonnes of CO2 equivalent (mtCO2e) per Renminbi/Chinese Yuan (RMB) of Revenue
Copy restricted. Please purchase to unlock this data.
2025

This table provides a simplified preview of selected climate targets data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.

Insights into JW (Cayman) Therapeutics's Greenhouse Gas Emissions Pathways

As of 2023, JW (Cayman) Therapeutics has set greenhouse gas (GHG) emissions reduction targets that cover its operational emissions (Scope 1 and 2), but not its value chain emissions (Scope 3). This means its reduction efforts currently focus on direct and purchased energy emissions.

Does JW (Cayman) Therapeutics have a target to reduce the emissions from its operations?

As of 2023, JW (Cayman) Therapeutics has set a target to reduce its operational greenhouse gas (GHG) emissions, specifically those from Scope 1 and Scope 2 sources.

JW (Cayman) Therapeutics's most ambitious operational target is to reduce these emissions by 40% by 2025, compared to a baseline of 0 Metric Tonnes of CO2 equivalent (mtCO2e) per Renminbi/Chinese Yuan (RMB) of Revenue in 2021.

JW (Cayman) Therapeutics has already surpassed its operational emissions reduction target, with 2023 levels falling below the 2025 value, achieving its climate goal ahead of schedule.

JW (Cayman) Therapeutics's Operational (Scope 1+2) Emissions Pathway

20212023202500000BaselineCurrent (-84%)Target 2025 (-40%)
Want Full Access to JW (Cayman) Therapeutics's Climate Targets Dataset?
Sign Up